Literature DB >> 18720925

Hyperglycosylated human chorionic gonadotropin and human chorionic gonadotropin free beta-subunit: tumor markers and tumor promoters.

Laurence A Cole1, Stephen A Butler.   

Abstract

Human chorionic gonadotropin (hCG) is a heterogeneous glycoprotein hormone comprising an alpha-subunit and beta-subunit that can vary in peptide and carbohydrate structure. After conception, hCG produced by early trophoblast cells acts on luteinizing hormone (LH)/hCG receptor corpus luteum cells to promote progesterone production and establish maternal recognition of pregnancy. hCG is not simply 1 molecule, and 2 variants of hCG appear to have independent activities in promoting tumor cell growth, invasion and malignancy. Hyperglycosylated hCG (H-hCG), produced by cytotrophoblast cells, is a marker for cytotrophoblast cells and tumor marker for gestational trophoblastic diseases. H-hCG promotes growth and invasion in these cells during pregnancy implantation, and growth in varying degrees by many nontrophoblastic neoplasms. beta-hCG is a marker of poor prognosis shown to promote growth and invasion in vitro, suggesting autocrine growth factor properties. Vaccines to beta-hCG have been successfully demonstrated, suggesting a potential adjuvant therapy in cancer treatment. Although sufficiently distinct in both structure and occurrence, similarities have been observed between H-hCG and beta-hCG as promoters of cell growth, invasion and malignancy. It is somewhat irregular for 2 structural variants of a molecule to have independent actions, actions very different to the gonadotropic function of the established hormone hCG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720925

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  6 in total

Review 1.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

Review 2.  Risk factors for massive hemorrhage during the treatment of cesarean scar pregnancy: a systematic review and meta-analysis.

Authors:  Yuan Zhang; Zhongyun Zhang; Xiaoyan Liu; Lei Zhang; Fanzhen Hong; Ming Lu
Journal:  Arch Gynecol Obstet       Date:  2020-11-21       Impact factor: 2.344

3.  Primary ovary choriocarcinoma: individual DNA polymorphic analysis as a strategy to confirm diagnosis and treatment.

Authors:  Pedro Exman; Tiago Kenji Takahashi; Gilka F Gattás; Vanessa Dionisio Cantagalli; Cristina Anton; Fernando Nalesso; Maria Del Pilar Estevez Diz
Journal:  Rare Tumors       Date:  2013-06-13

Review 4.  Human Chorionic Gonadotropin and Early Embryogenesis: Review.

Authors:  Sophie Perrier d'Hauterive; Romann Close; Virginie Gridelet; Marie Mawet; Michelle Nisolle; Vincent Geenen
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

Review 5.  Developing a deeper insight into reproductive biomarkers.

Authors:  Braira Wahid; Hamid Bashir; Muhammad Bilal; Khansa Wahid; Aleena Sumrin
Journal:  Clin Exp Reprod Med       Date:  2017-12-31

Review 6.  Human Chorionic Gonadotrophin: New Pleiotropic Functions for an "Old" Hormone During Pregnancy.

Authors:  Virginie Gridelet; Sophie Perrier d'Hauterive; Barbara Polese; Jean-Michel Foidart; Michelle Nisolle; Vincent Geenen
Journal:  Front Immunol       Date:  2020-03-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.